Treatment of IV 4 mg/kg 2 mg/kg 1 year HER2-positive every 1 localised breast week cancer following surgery, and in SC - 600 mg 1 year association with every 3 chemotherapy and, weeks if applicable, radiotherapy. Locally Advanced IV 8 mg/kg 6 mg/kg 1 year Breast Cancer trial 3 weeks Treatment of HER2-positive SC - 600 mg 1 year locally advanced every 3 breast cancer in weeks combination with neoadjuvant chemotherapy followed by adjuvant HERCEPTIN. Metastatic Breast IV 4 mg/kg 2 mg/kg Until disease Cancer every 1 progression week Treatment of patients with metastatic breast cancer who have tumours that overexpress HER2: As monotherapy for the treatment of those patients who have received one or more chemotherapy regimens for their SC - 600 mg Until disease metastatic disease; trial 3 progression weeks In combination with taxanes for the treatment of those patients who have not received chemotherapy for their metastatic disease; or
Treatment of HER2-positive localised breast cancer following surgery, and in association with chemotherapy and, if applicable, radiotherapy. IV 4 mg/kg 2 mg/kg every 1 week 1 year SC - 600 mg every 3 weeks 1 year Locally Advanced Breast Cancer Treatment of HER2-positive locally advanced breast cancer in combination with neoadjuvant chemotherapy followed by adjuvant HERCEPTIN. IV 8 mg/kg 6 mg/kg 3 weeks 1 year SC - 600 mg every 3 weeks 1 year Metastatic Breast Cancer Treatment of patients with metastatic breast cancer who have tumours that overexpress HER2: As monotherapy for the treatment of those patients who have received one or more chemotherapy regimens for their metastatic disease; In combination with taxanes for the treatment of those patients who have not received chemotherapy for their metastatic disease; or IV 4 mg/kg 2 mg/kg every 1 week Until disease progression SC - 600 mg 3 weeks Until disease progression trial trial
auspar-trastuzumab-150803.docx